The Next Generation Biotech Media
On January 15th, Pfizer announced FDA approval for its tyrosine kinase inhibitor, Xalkori, which can be used in pediatric patients one year of age and older and young adults with …
Read More
Cancer therapy without a doubt will be one of the most trending topics in 2021. As several contenders push their way into the field, on January 13, Japanese biopharma, Takeda …
Read More
In recent times, several big pharma have collaborated with small companies in the immuno-oncology field. Last September, Pfizer made a $200 million investment to collaborate with CStone Pharmaceuticals. Now Novartis …
Read More
On January 5th, Daiichi Sankyo announced the submission of a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for teserpaturev (G47∆), an oncolytic virus, for …
Read More
The new year has brought good news for Boston-based Ikena oncology, which raised $120 million to push its pipeline of patient-specific, next-generation targeted oncology and immunometabolism therapies. This funding comes …
Read More
On December 28th, Merck and AstraZeneca announced that their PARP inhibitor Lynparza received approval from Japan to treat ovarian, prostate, and pancreatic cancers. The approvals by the Japanese Ministry of Health, …
Read More
Cancer is a particularly challenging problem to solve since it can learn to override and resist treatment. Multiple mechanisms can help cancer evade therapy and develop resistance. In a new …
Read More
On December 23rd, Roche announced that it had received approval for the usage of Phesgo, a therapy containing two monoclonal antibodies against the human epidermal growth factor receptor 2 (HER2) …
Read More
The Center for Drug Evaluation (CDE) accepted Bayer’s clinical application for BAY 2416964 tablets submitted in category 1 of chemical drugs on October 16th. On December 17th, it has given …
Read More
On December 21st, Servier announced that it would acquire Agios Pharmaceuticals for up to $2 billion. This acquisition will give Servier two FDA approved therapeutics, TIBSOVO, and IDHIFA, as well …
Read More